{"hands_on_practices": [{"introduction": "The pancreas is a dual-function gland, with its endocrine cells organized into the islets of Langerhans. Critically, these islets are not distributed uniformly throughout the organ; their density varies between the head, body, and tail. This exercise challenges you to integrate gross anatomical data (the mass of different pancreatic regions) with microscopic data (regional islet density) to calculate a total population [@problem_id:5141488]. This practice is fundamental for appreciating how quantitative histological analysis can provide a complete picture of an organ's cellular composition.", "problem": "A human pancreas can be partitioned anatomically into head, body, and tail regions, each with distinct enrichment of endocrine tissue, with the tail typically exhibiting higher islet cell concentration than the head and body. Consider a pancreas with total mass $100\\,\\mathrm{g}$, where the head, body, and tail have masses $40\\,\\mathrm{g}$, $35\\,\\mathrm{g}$, and $25\\,\\mathrm{g}$, respectively. Histological sampling finds that the mean islet number density per gram of tissue is regionally uniform within each segment but differs across segments, measured as $1.5 \\times 10^{3}$ islets per gram in the head, $2.0 \\times 10^{3}$ islets per gram in the body, and $3.0 \\times 10^{3}$ islets per gram in the tail.\n\nStarting from the fundamental definition that a count obtained from a density measured per unit mass must be accumulated over the organ by summing contributions from each region according to their tissue mass, compute the total number of pancreatic islets in this organ.\n\nRound your answer to four significant figures and report it as a pure number of islets (dimensionless).", "solution": "The problem statement is evaluated to be valid as it is scientifically grounded, self-contained, and well-posed. The provided anatomical data and histological densities are consistent with established biological facts regarding the human pancreas. The masses of the constituent parts sum to the total mass ($40\\,\\mathrm{g} + 35\\,\\mathrm{g} + 25\\,\\mathrm{g} = 100\\,\\mathrm{g}$), ensuring internal consistency. The instruction to calculate the total number of islets by summing the contributions from each region is a clear and logical procedure.\n\nLet us define the relevant physical quantities.\nThe total number of islets, $N_{total}$, is the sum of the number of islets in the head ($N_{h}$), body ($N_{b}$), and tail ($N_{t}$) of the pancreas.\n$$\nN_{total} = N_{h} + N_{b} + N_{t}\n$$\n\nThe problem statement provides the mass for each anatomical region:\n- Mass of the head, $M_{h} = 40\\,\\mathrm{g}$\n- Mass of the body, $M_{b} = 35\\,\\mathrm{g}$\n- Mass of the tail, $M_{t} = 25\\,\\mathrm{g}$\n\nIt also provides the mean islet number density per unit mass for each region, which is denoted by $\\rho$:\n- Density in the head, $\\rho_{h} = 1.5 \\times 10^{3}\\,\\mathrm{islets/g}$\n- Density in the body, $\\rho_{b} = 2.0 \\times 10^{3}\\,\\mathrm{islets/g}$\n- Density in the tail, $\\rho_{t} = 3.0 \\times 10^{3}\\,\\mathrm{islets/g}$\n\nThe fundamental definition, as specified in the problem, dictates that the number of islets in a region with uniform density is the product of the number density and the mass of that region. Therefore, for each segment:\n$$\nN_{h} = \\rho_{h} \\times M_{h}\n$$\n$$\nN_{b} = \\rho_{b} \\times M_{b}\n$$\n$$\nN_{t} = \\rho_{t} \\times M_{t}\n$$\n\nSubstituting these expressions into the equation for the total number of islets, we get:\n$$\nN_{total} = (\\rho_{h} \\times M_{h}) + (\\rho_{b} \\times M_{b}) + (\\rho_{t} \\times M_{t})\n$$\n\nNow, we substitute the given numerical values into this equation. The units of mass ($\\mathrm{g}$) and the units of density ($\\mathrm{islets/g}$) are consistent, yielding a dimensionless count for the number of islets.\n\n$$\nN_{total} = (1.5 \\times 10^{3}\\,\\mathrm{g}^{-1} \\times 40\\,\\mathrm{g}) + (2.0 \\times 10^{3}\\,\\mathrm{g}^{-1} \\times 35\\,\\mathrm{g}) + (3.0 \\times 10^{3}\\,\\mathrm{g}^{-1} \\times 25\\,\\mathrm{g})\n$$\n\nWe can compute the contribution from each region:\n- Contribution from the head: $N_{h} = 1.5 \\times 10^{3} \\times 40 = 60 \\times 10^{3} = 60000$\n- Contribution from the body: $N_{b} = 2.0 \\times 10^{3} \\times 35 = 70 \\times 10^{3} = 70000$\n- Contribution from the tail: $N_{t} = 3.0 \\times 10^{3} \\times 25 = 75 \\times 10^{3} = 75000$\n\nSumming these contributions gives the total number of islets:\n$$\nN_{total} = 60000 + 70000 + 75000 = 205000\n$$\n\nThe problem requires the final answer to be rounded to four significant figures. The calculated value is $205000$. To express this number with four significant figures, it must be written in scientific notation.\n$$\nN_{total} = 2.050 \\times 10^{5}\n$$\nThis representation unambiguously indicates that the trailing zero after the digit $5$ is significant, fulfilling the requirement of four significant figures.", "answer": "$$\n\\boxed{2.050 \\times 10^{5}}\n$$", "id": "5141488"}, {"introduction": "The main pancreatic duct is the central conduit for exocrine secretions, and its diameter is a vital indicator of pancreatic health on clinical imaging. However, a \"normal\" size is not a single value; the duct naturally tapers from head to tail, requiring segment-specific knowledge for accurate assessment. This problem asks you to step into the role of a clinician and evaluate a radiological measurement against established anatomical norms, highlighting the direct link between precise anatomical knowledge and diagnostic reasoning [@problem_id:5141492].", "problem": "A radiology report for a patient aged $45$ years describes the main pancreatic duct (Wirsung) as follows: at the mid-body of the pancreas, measured orthogonally to the duct axis on high-resolution magnetic resonance cholangiopancreatography, the inner luminal diameter is $2.5\\,\\mathrm{mm}$. The head and tail segments otherwise appear unremarkable, and the measurement was obtained in the fasting state without pharmacologic stimulation. Using segment-specific anatomical norms for duct caliber that recognize proximal-to-distal tapering and define dilation as exceeding the accepted upper limit for the measured segment, which of the following classifications and justifications is most appropriate for the body measurement of $2.5\\,\\mathrm{mm}$?\n\nA. The body measurement is normal because the main pancreatic duct shares a uniform upper limit of $3.0\\,\\mathrm{mm}$ across the head and body segments.\n\nB. The body measurement is mildly dilated because the upper limit of normal in the body is approximately $2.0\\,\\mathrm{mm}$, and $2.5\\,\\mathrm{mm}  2.0\\,\\mathrm{mm}$.\n\nC. The body measurement is normal because postprandial physiological variation allows the duct to reach $4.0\\,\\mathrm{mm}$ in the body.\n\nD. The body measurement is indeterminate unless the tail measurement also exceeds $3.0\\,\\mathrm{mm}$.\n\nE. The body measurement is a normal age-related variant because duct diameter increases linearly by $0.1\\,\\mathrm{mm}$ per decade from a $2.0\\,\\mathrm{mm}$ baseline.", "solution": "The problem statement is first subjected to validation.\n\n**Step 1: Extract Givens**\n- Patient Age: $45$ years\n- Structure: Main pancreatic duct (Wirsung)\n- Measurement Location: Mid-body of the pancreas\n- Measurement Value: Inner luminal diameter = $2.5\\,\\mathrm{mm}$\n- Measurement Technique: Orthogonal to the duct axis on high-resolution magnetic resonance cholangiopancreatography (MRCP)\n- Patient State: Fasting, no pharmacologic stimulation\n- Associated Findings: Head and tail segments appear unremarkable\n- Guiding Principle for Interpretation: Use segment-specific anatomical norms for duct caliber that recognize proximal-to-distal tapering.\n- Definition of Dilation: Exceeding the accepted upper limit for the measured segment.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, well-posed, and objective. It is rooted in the established medical fields of systematic anatomy and diagnostic radiology. The presented data, such as patient age, measurement value ($2.5\\,\\mathrm{mm}$), and imaging modality (MRCP), are realistic. The terminology is precise and standard for the discipline. The problem asks for a classification based on well-documented anatomical norms, specifically referencing the principle of segment-specific diameters and proximal-to-distal tapering of the main pancreatic duct. This structure does not violate any principles of scientific or logical soundness. It is not incomplete, as it provides all necessary information for an individual with the expected domain knowledge to arrive at a conclusion. It is a valid problem testing the application of anatomical knowledge.\n\n**Step 3: Verdict and Action**\nThe problem statement is valid. A detailed solution will be derived.\n\n**Derivation**\n\nThe central task is to classify the measured diameter of the main pancreatic duct (MPD) at the pancreatic body, which is given as $d_{\\text{measured}} = 2.5\\,\\mathrm{mm}$. The problem requires this classification to be based on segment-specific norms that account for the natural tapering of the duct from head to tail.\n\nIn clinical anatomy and radiology, the MPD is known to have a progressively decreasing caliber from the pancreatic head (proximal) to the tail (distal). The widely accepted upper limits of normal (ULN) for an adult in a fasting state, often referred to as the \"3-2-1 rule,\" are:\n- Pancreatic Head: $\\leq 3\\,\\mathrm{mm}$\n- Pancreatic Body: $\\leq 2\\,\\mathrm{mm}$\n- Pancreatic Tail: $\\leq 1\\,\\mathrm{mm}$\n\nSlight variations on these values exist in the literature, but the principle of tapering and these approximate thresholds are standard. The patient's measurement was taken at the mid-body of the pancreas. Therefore, the relevant ULN is that for the body, which is approximately $2.0\\,\\mathrm{mm}$.\n\nThe provided measurement is $d_{\\text{measured}} = 2.5\\,\\mathrm{mm}$.\nThe upper limit of normal for the body is $d_{\\text{ULN, body}} \\approx 2.0\\,\\mathrm{mm}$.\n\nComparing the two values:\n$d_{\\text{measured}} = 2.5\\,\\mathrm{mm}$\n$d_{\\text{ULN, body}} = 2.0\\,\\mathrm{mm}$\nSince $2.5\\,\\mathrm{mm} > 2.0\\,\\mathrm{mm}$, the duct at the measured segment exceeds the upper limit of normal. According to the problem's definition, this constitutes dilation. A caliber of $2.5\\,\\mathrm{mm}$ where the limit is $2.0\\,\\mathrm{mm}$ is typically described as mild dilation.\n\nThe patient's age is $45$ years. While ductal diameter can increase slightly with age (often cited as approximately $0.1\\,\\mathrm{mm}$ per decade over $40$ years), this does not fundamentally alter the primary classification. For a $45$-year-old, the age-adjusted ULN might be considered $2.0\\,\\mathrm{mm} + (0.5 \\text{ decades} \\times 0.1\\,\\mathrm{mm}/\\text{decade}) = 2.05\\,\\mathrm{mm}$. The measured value of $2.5\\,\\mathrm{mm}$ still clearly exceeds this adjusted limit.\n\n**Option-by-Option Analysis**\n\n**A. The body measurement is normal because the main pancreatic duct shares a uniform upper limit of $3.0\\,\\mathrm{mm}$ across the head and body segments.**\nThis statement is factually incorrect. It violates the principle of proximal-to-distal tapering, which the problem explicitly asks to consider. The upper limit of normal is not uniform; it is approximately $3.0\\,\\mathrm{mm}$ in the head and decreases to approximately $2.0\\,\\mathrm{mm}$ in the body.\n**Verdict: Incorrect.**\n\n**B. The body measurement is mildly dilated because the upper limit of normal in the body is approximately $2.0\\,\\mathrm{mm}$, and $2.5\\,\\mathrm{mm}  2.0\\,\\mathrm{mm}$.**\nThis option correctly states the accepted upper limit of normal for the pancreatic body ($\\approx 2.0\\,\\mathrm{mm}$). It correctly applies this norm to the measured value ($2.5\\,\\mathrm{mm}$) and logically concludes that the duct is dilated. The qualitative descriptor \"mildly\" is appropriate for the magnitude of the dilation ($0.5\\,\\mathrm{mm}$ over the limit). This aligns perfectly with the derivation.\n**Verdict: Correct.**\n\n**C. The body measurement is normal because postprandial physiological variation allows the duct to reach $4.0\\,\\mathrm{mm}$ in the body.**\nThis option is incorrect on two grounds. First, the problem specifies the measurement was made in the **fasting state**, rendering postprandial (after a meal) changes irrelevant. Second, a duct diameter of $4.0\\,\\mathrm{mm}$ in the body would represent significant dilation, not a normal physiological response, even postprandially.\n**Verdict: Incorrect.**\n\n**D. The body measurement is indeterminate unless the tail measurement also exceeds $3.0\\,\\mathrm{mm}$.**\nThis statement is incorrect. A segmental dilation in the body can be identified and classified independently of the tail. Furthermore, the proposed threshold for the tail ($3.0\\,\\mathrm{mm}$) is anatomically nonsensical; the tail is the narrowest part, with a ULN of approximately $1.0\\,\\mathrm{mm}$. A tail measuring $3.0\\,\\mathrm{mm}$ would be severely dilated and would contradict the normal tapering anatomy.\n**Verdict: Incorrect.**\n\n**E. The body measurement is a normal age-related variant because duct diameter increases linearly by $0.1\\,\\mathrm{mm}$ per decade from a $2.0\\,\\mathrm{mm}$ baseline.**\nThis option misinterprets the significance of age-related changes. As calculated in the derivation, even when accounting for a standard age-related increase for a $45$-year-old, the expected ULN would be approximately $2.05\\,\\mathrm{mm}$. The measurement of $2.5\\,\\mathrm{mm}$ is still substantially larger than this age-adjusted norm and thus represents dilation, not a normal variant. The primary assessment is based on the segmental norm, which is exceeded here.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{B}$$", "id": "5141492"}, {"introduction": "An organ's viability is entirely dependent on its blood supply. The pancreas occupies a critical location, receiving blood from two of the abdomen's main arteries: the celiac trunk and the superior mesenteric artery ($SMA$). This thought experiment simulates acute vascular emergencies to test your understanding of these supply territories and the crucial role of collateral circulatory pathways like the pancreaticoduodenal arcades [@problem_id:5141533]. Mastering this type of anatomical reasoning is essential for predicting the consequences of vascular disease.", "problem": "A patient presents with acute upper abdominal pain. Imaging demonstrates either an acute thrombotic occlusion of the celiac trunk or an acute embolic occlusion of the superior mesenteric artery (SMA). You are asked to predict which intrapancreatic territories are at greatest risk of ischemia in each scenario by reasoning from first principles about arterial territories and collateral arcades.\n\nBase your reasoning on the following well-established facts and definitions:\n- Foregut derivatives are supplied by the celiac trunk, midgut derivatives by the SMA. The head of the pancreas straddles the foregut–midgut junction.\n- The superior pancreaticoduodenal arteries arise from the gastroduodenal artery (a branch in the celiac territory) and the inferior pancreaticoduodenal arteries arise from the SMA; these form robust anterior and posterior pancreaticoduodenal arcades around the pancreatic head.\n- The splenic artery supplies the neck, body, and tail of the pancreas via named branches (dorsal pancreatic, great pancreatic, caudal pancreatic, among others).\n- In the acute setting, flow across established arcades can redistribute along pressure gradients, but small-caliber parenchymal microcollaterals within the body and tail are typically insufficient to fully compensate for a sudden loss of inflow.\n- Assume a “classic” branching pattern as above and patent pancreaticoduodenal arcades of usual caliber.\n\nWhich option best predicts the pancreatic ischemic zones in each case?\nA. Celiac trunk occlusion: ischemia of the pancreatic neck, body, and tail; head remains viable via retrograde inflow from the SMA through the inferior pancreaticoduodenal arteries. SMA occlusion: ischemia of the uncinate process and inferior head; body and tail remain viable via splenic branches.\nB. Celiac trunk occlusion: only the pancreatic tail becomes ischemic; SMA occlusion: the entire head and body become ischemic, with the tail spared.\nC. Celiac trunk occlusion: the entire pancreas becomes ischemic due to loss of the dominant inflow; SMA occlusion: the entire pancreas remains viable due to splenic collaterals.\nD. Celiac trunk occlusion: the pancreatic head becomes ischemic because the superior pancreaticoduodenal arteries are compromised despite intact SMA; SMA occlusion: the pancreatic body and tail become ischemic due to loss of the inferior pancreatic inflow.\nE. Celiac trunk occlusion: only the uncinate process becomes ischemic due to its deep location; SMA occlusion: only the superior aspect of the head becomes ischemic due to loss of celiac inflow.", "solution": "The problem statement will first be validated for scientific soundness, self-consistency, and clarity before a solution is attempted.\n\n### Step 1: Extract Givens\n\nThe following information is provided in the problem statement:\n- **Clinical Scenario**: A patient has either an acute thrombotic occlusion of the `celiac trunk` or an acute embolic occlusion of the `superior mesenteric artery` (`SMA`).\n- **Objective**: Predict the intrapancreatic territories at greatest risk of ischemia for each scenario.\n- **Anatomical and Physiological Principles**:\n    1.  `Foregut` derivatives are supplied by the `celiac trunk`; `midgut` derivatives are supplied by the `SMA`. The `head of the pancreas` straddles the `foregut`-`midgut` junction.\n    2.  The `superior pancreaticoduodenal arteries` (`SPDA`) originate from the `gastroduodenal artery` (`GDA`), which is a branch within the `celiac trunk` territory.\n    3.  The `inferior pancreaticoduodenal arteries` (`IPDA`) originate from the `SMA`.\n    4.  The `SPDA` and `IPDA` form robust anterior and posterior `pancreaticoduodenal arcades` around the `pancreatic head`.\n    5.  The `splenic artery` supplies the `neck`, `body`, and `tail` of the `pancreas` via the `dorsal pancreatic`, `great pancreatic`, and `caudal pancreatic` arteries.\n    6.  In acute occlusion, flow redistribution across established `arcades` is possible. However, small-caliber parenchymal microcollaterals in the `body` and `tail` are insufficient for compensation.\n    7.  We must assume a \"classic\" branching pattern and patent `pancreaticoduodenal arcades` of usual caliber.\n\n### Step 2: Validate Using Extracted Givens\n\n- **Scientifically Grounded**: The problem is firmly rooted in established principles of vascular anatomy and pathophysiology. The described arterial supply to the `pancreas`—a dual supply to the `head` from the `celiac trunk` and `SMA`, and a primary supply to the `body` and `tail` from the `celiac trunk` via the `splenic artery`—is the standard textbook model. The concept of ischemia resulting from arterial occlusion and the role of collateral circulation are fundamental to medicine.\n- **Well-Posed**: The problem presents two distinct, well-defined scenarios and asks for a prediction based on a given set of rules and assumptions. The assumption of a \"classic\" branching pattern and patent `arcades` ensures that a unique, logical solution can be derived.\n- **Objective**: The language is precise and technical, free from subjective or ambiguous terminology.\n\nThe problem statement is found to be valid. It is scientifically sound, well-posed, and objective. It contains no contradictions, missing information, or unrealistic premises.\n\n### Step 3: Derivation of the Solution from First Principles\n\nWe will analyze each scenario based on the provided anatomical and physiological facts.\n\n**Scenario 1: Acute Occlusion of the Celiac Trunk**\n\n1.  **Direct Consequences**: An occlusion at the origin of the `celiac trunk` stops all anterograde blood flow into its three major branches: the `left gastric artery`, the `common hepatic artery`, and the `splenic artery`.\n2.  **Impact on Pancreatic Body and Tail**: The `neck`, `body`, and `tail` of the `pancreas` are primarily supplied by branches of the `splenic artery` (e.g., `dorsal pancreatic`, `great pancreatic`, `caudal pancreatic arteries`). Since the `splenic artery` is a direct branch of the `celiac trunk`, its flow is now occluded. The problem explicitly states that local microcollaterals in this region are insufficient to compensate for an acute loss of inflow. Therefore, the `neck`, `body`, and `tail` of the `pancreas` will become ischemic.\n3.  **Impact on Pancreatic Head**: The `head of the pancreas` has a dual supply. The superior portion is supplied by the `superior pancreaticoduodenal arteries` (`SPDA`), which arise from the `gastroduodenal artery` (`GDA`), a branch of the `common hepatic artery` from the `celiac trunk`. This inflow is now lost. However, the inferior portion is supplied by the `inferior pancreaticoduodenal arteries` (`IPDA`), which arise from the `SMA`. In this scenario, the `SMA` is patent. The problem states that the `pancreaticoduodenal arcades` connecting the `SPDA` and `IPDA` systems are \"robust\" and \"patent\". Therefore, blood from the `SMA` can flow into the `IPDA` and then travel retrogradely through the `arcades` to perfuse the territory of the `SPDA`. This collateral pathway is sufficient to maintain the viability of the entire `pancreatic head`.\n4.  **Conclusion for Scenario 1**: Ischemia is predicted for the `neck`, `body`, and `tail` of the `pancreas`. The `head` is predicted to remain viable due to collateral flow from the `SMA`.\n\n**Scenario 2: Acute Occlusion of the Superior Mesenteric Artery (SMA)**\n\n1.  **Direct Consequences**: An occlusion of the `SMA` stops all anterograde blood flow to its branches, including the `IPDA`. The `celiac trunk` and its branches remain patent and well-perfused.\n2.  **Impact on Pancreatic Body and Tail**: The `neck`, `body`, and `tail` of the `pancreas` are supplied by the `splenic artery`, a `celiac trunk` branch. Since the `celiac trunk` is unaffected, these regions will remain fully perfused and viable.\n3.  **Impact on Pancreatic Head**: The `head of the pancreas` is supplied by both the `SPDA` (from the `celiac trunk`) and the `IPDA` (from the `SMA`). The occlusion of the `SMA` cuts off inflow to the `IPDA`. However, the `celiac trunk` is patent, providing strong antegrade flow to the `SPDA`. This flow can cross the \"robust\" `pancreaticoduodenal arcades` to perfuse the `IPDA` territory retrogradely. While the arcades provide a rescue pathway, the region most directly dependent on the occluded vessel—the `SMA`—is the one at \"greatest risk of ischemia\". This territory corresponds to the anatomical distribution of the `IPDA`, which primarily supplies the inferior part of the `pancreatic head` and the `uncinate process`.\n4.  **Conclusion for Scenario 2**: The `neck`, `body`, and `tail` of the `pancreas` remain viable. The `uncinate process` and the inferior portion of the `head` are at the greatest risk of ischemia.\n\n### Evaluation of Options\n\n- **A. Celiac trunk occlusion: ischemia of the pancreatic neck, body, and tail; head remains viable via retrograde inflow from the SMA through the inferior pancreaticoduodenal arteries. SMA occlusion: ischemia of the uncinate process and inferior head; body and tail remain viable via splenic branches.**\n  - This option perfectly matches the conclusions derived from first principles for both scenarios. The description of ischemic zones and viable zones, along with the reasoning for collateral flow, is correct.\n  - **Verdict: Correct.**\n\n- **B. Celiac trunk occlusion: only the pancreatic tail becomes ischemic; SMA occlusion: the entire head and body become ischemic, with the tail spared.**\n  - The first part is incorrect. Celiac occlusion compromises the entire `splenic artery`, thus endangering the `neck` and `body` in addition to the `tail`.\n  - The second part is incorrect. `SMA` occlusion does not affect the `body` (supplied by the `celiac trunk`), and the `head` should be largely protected by collateral flow from the `SPDA`.\n  - **Verdict: Incorrect.**\n\n- **C. Celiac trunk occlusion: the entire pancreas becomes ischemic due to loss of the dominant inflow; SMA occlusion: the entire pancreas remains viable due to splenic collaterals.**\n  - The first part is incorrect. It fails to account for the robust collateral supply to the `head` from the `SMA` via the `pancreaticoduodenal arcades`.\n  - The second part is incorrect. `Splenic collaterals` do not supply the `head`, and the inferior `head`/`uncinate process` remains at significant risk despite other collaterals.\n  - **Verdict: Incorrect.**\n\n- **D. Celiac trunk occlusion: the pancreatic head becomes ischemic because the superior pancreaticoduodenal arteries are compromised despite intact SMA; SMA occlusion: the pancreatic body and tail become ischemic due to loss of the inferior pancreatic inflow.**\n  - The first part is incorrect. It explicitly ignores the functionality of the patent `pancreaticoduodenal arcades`, which is a central premise of the problem.\n  - The second part is anatomically incorrect. The `pancreatic body` and `tail` are not supplied by the `SMA` or its \"inferior pancreatic inflow\" (`IPDA`); they are supplied by the `celiac trunk`'s `splenic artery`.\n  - **Verdict: Incorrect.**\n\n- **E. Celiac trunk occlusion: only the uncinate process becomes ischemic due to its deep location; SMA occlusion: only the superior aspect of the head becomes ischemic due to loss of celiac inflow.**\n  - The first part is incorrect. `Celiac occlusion` affects the `body` and `tail` most severely; the `uncinate process`, part of the `head`, is likely to be spared.\n  - The second part is incorrect. `SMA occlusion` does not cause \"loss of celiac inflow,\" and it is the *inferior* aspect of the `head` (supplied by the `SMA`) that is at risk, not the superior aspect.\n  - **Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "5141533"}]}